Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M16-067: Risankizumab induction therapy in moderately to severely active ulcerative colitis
jRCT2080223940Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Risankizumab induction with Placebo induction (2 arms). Started Jun 2018; status: completed.
02
Drugs
risankizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080223940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223940.